BioCryst Pharmaceuticals Inc. (BCRX) Trading Up 13.8%
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)’s share price was up 13.8% during trading on Tuesday . The company traded as high as $4.79 and last traded at $4.77, with a volume of 1,610,615 shares traded. The stock had previously closed at $4.19.
A number of equities analysts have commented on BCRX shares. FBR & Co reaffirmed a “buy” rating and set a $6.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Wednesday, July 6th. Jefferies Group raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research report on Wednesday, June 1st. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Monday, May 9th. JPMorgan Chase & Co. reissued a “hold” rating on shares of BioCryst Pharmaceuticals in a research report on Friday, August 5th. Finally, JMP Securities cut shares of BioCryst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 4th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the company’s stock. BioCryst Pharmaceuticals has an average rating of “Hold” and an average target price of $7.89.
The company’s market capitalization is $368.46 million. The company’s 50-day moving average price is $3.28 and its 200-day moving average price is $3.24.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Thursday, August 4th. The biotechnology company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.04. The company earned $4.80 million during the quarter, compared to analysts’ expectations of $3.92 million. During the same period in the previous year, the company posted $0.06 earnings per share. The company’s quarterly revenue was down 81.4% compared to the same quarter last year. On average, analysts expect that BioCryst Pharmaceuticals Inc. will post ($1.04) EPS for the current year.
Several large investors have made changes to their positions in BCRX. Jennison Associates LLC raised its stake in shares of BioCryst Pharmaceuticals by 1.8% in the fourth quarter. Jennison Associates LLC now owns 1,348,563 shares of the biotechnology company’s stock valued at $13,917,000 after buying an additional 24,014 shares in the last quarter. Globeflex Capital L P acquired a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter valued at about $1,241,000. Finally, Morgan Stanley raised its stake in shares of BioCryst Pharmaceuticals by 13.9% in the fourth quarter. Morgan Stanley now owns 103,804 shares of the biotechnology company’s stock valued at $1,071,000 after buying an additional 12,646 shares in the last quarter.
BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.